key: cord-0256168-utve8dof
authors: Carazo, S.; Talbot, D.; Boulianne, N.; Brisson, M.; Gilca, R.; Deceuninck, G.; Brousseau, N.; Drolet, M.; Ouakki, M.; Sauvageau, C.; Barkati, S.; Fortin, E.; Carignan, A.; De Wals, P.; Skowronski, D. M.; De Serres, G.
title: Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.19.21260445
sha: 10a9674315db52c26d77aebf3f1191ffd4906240
doc_id: 256168
cord_uid: utve8dof

Introduction: In Canada, first and second doses of mRNA vaccines against SARS-CoV-2 were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains uncertain. We estimated one- and two-dose mRNA vaccine effectiveness (VE) among healthcare workers (HCWs) in Quebec, Canada including protection against varying outcome severity, variants of concern (VOC), and the stability of single-dose protection out to 16 weeks post-vaccination. Methods: A test-negative design compared vaccination among SARS-CoV-2 test-positive and weekly-matched (10:1), randomly-sampled, test-negative HCWs using linked surveillance and immunization databases. Vaccine status was defined by one dose [≥]14 days or two doses [≥]7 days before illness onset or specimen collection. Adjusted VE was estimated by conditional logistic regression. Results: Primary analysis included 5,316 cases and 53,160 controls. Single-dose VE was 70% (95%CI: 68-73) against SARS-CoV-2 infection, 73% (95%CI: 71-75) against COVID-19 illness and 97% (95%CI: 92-99) against associated hospitalization. Two-dose VE was 86% (95%CI: 81-90) and 93% (95%CI: 89-95), respectively, with no associated hospitalizations. VE was higher for non-VOC than VOC (73% Alpha) among single-dose (77%, 95%CI: 73-81 versus 63%, 95%CI: 57-67) but not two-dose recipients (87%, 95%CI: 57-96 versus 94%, 95%CI: 89-96). Across 16 weeks, no decline in single-dose VE was observed with appropriate stratification based upon prioritized vaccination determined by higher versus lower likelihood of direct patient contact. Conclusion: One mRNA vaccine dose provided substantial and sustained protection to HCWs extending at least four months post-vaccination. In circumstances of vaccine shortage, delaying the second dose may be a pertinent public health strategy to consider.

In December 2020, two mRNA vaccines against SARS-CoV-2 were authorized in Canada based upon a schedule of two doses spaced 3 weeks (BNT162b2 (Pfizer-BioNTech)) or 4 weeks (mRNA-

The study period included HCWs with specimen reference date between January 17 (epidemiological week 3) and June 5 (week 22), 2021 (Figure 1 ), taking into account the immunization start-date and a several-week lag for vaccine effect. Data were extracted on June 17 th 2021, allowing additional 14-day lag to capture associated hospitalizations.

Vaccination status was defined in relation to the reference date. In primary analysis, a participant was deemed a single-or two-dose vaccinee if the doses were received ≥14 days or ≥7 days before the reference date (with day of vaccination being day 0), respectively, requiring ≥3 weeks between doses. HCWs who received no vaccine doses at any time on or before the reference date were considered unvaccinated whereas those who received the first dose <14 days or second dose <7 days prior were excluded. RT-PCR confirmed SARS-CoV-2 outcomes of varying severity were explored, including: any infection; symptomatic infection of any severity (specified hereafter as COVID-19); and COVID-19-related hospitalization (occurring within 30 days of illness onset).

Odds ratios (OR) and their 95% confidence intervals (95%CI) among one-and two-dose vaccinees relative to unvaccinated HCWs were estimated by multivariate conditional logistic regression using the matching week as strata and adjusting for potential confounders. VE and 95% CIs were derived as: (1 − ) × 100.

Adjustment variables included: age group (18-29, 30-39, 40-49, 50-59, 60-74 years); sex;

healthcare setting (hospitals and local community health centers, LTCFs, rehabilitation centers, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint home care, other); occupation (nurse, nursing assistant, personal healthcare support worker, other technical and health assisting occupations, administrative and management staff, healthcare technician, social workers, others); region of the healthcare setting (18 in Quebec); and presence of 17 possible comorbidities associated with increased COVID-19 hospitalization risk (known for ~90% of HCWs) [18] .

In addition to overall primary analyses by outcome severity, sensitivity analyses included: (a) stratifying by HCW priority group based upon those targeted before January 31 (week 5) or since February 21 (week 8) reflecting higher and lower frequency of direct patient contact and baseline infection risk, respectively; (b) stratifying by VOC status; (c) restricting to HCWs with data on 17 pre-existing conditions of comorbidity (at least one, at least two or by the number of 0, 1, 2, 3, 4, ≥5 conditions); and (d) stratifying by reason for testing (compatible symptoms, outbreak or systematic screening).

This study was conducted as a surveillance and evaluation protocol with the legal mandate of the National Director of Public Health of Quebec and with the requirement for ethics approval thereby waived under the Public Health Act. It has been approved by the Research ethics board of the CHU de Québec-Université Laval.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure S1) , of which 10.8% cases and 11.8% controls vaccinated 0-13 days or 0-6 days before the first or second dose, respectively, were excluded from primary analyses.

At their reference date, 23.8% of cases and 49.1% of controls had received one dose ≥14 days earlier and 0.9% of cases and 3.9% of controls had received two doses ≥7 days earlier. The percentage of controls vaccinated with at least one dose ≥14 days before the reference date increased with age, from 49.1% in 18-29-year-olds to 61.5% among 60-74-year-olds (Supplementary Figure S2) . For those who received 2 doses, the median interval between doses was nearly 16 weeks (111 days for cases and 112 days for controls). The median follow-up time for one-dose vaccinees was 56 days and for two-dose vaccinees was 18 days. Among all cases, 80.5% had COVID-19-related symptoms, 1.7% were hospitalized and one unvaccinated HCW died . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure S2 ).

One-dose VE against COVID-19 was 76-78% between 2-and 7-weeks post-vaccination, declining slightly to about 70% between 9-and 16-weeks post-vaccination (<1% were vaccinated >16 weeks prior) ( Figure 2 ). Follow-up after two doses was too short for corresponding interval analyses.

By HCW priority group . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021.

Among HCWs first targeted for vaccination before week 5 (because of highest likelihood of direct patient contact and baseline infection risk), VE during the period 0-13 days after the first dose (when no vaccine effect is expected) was highly negative (-101.6%, 95%CI: -139.9 to -69.5).

Conversely, among HCWs first vaccinated after week 8 (at lower baseline infection risk), VE during the period 0-13 days was significantly higher at 43.7% (95%CI: 31.9-53.5). Thereafter, the earlier vs. later targeted HCWs had lower VE overall across the 2-16-week analysis period (52.2%, 95%CI: 47.1-56.9 vs 77.4%, 95%CI: 73.0-81.1), with neither target group showing decline in protection over that extended follow-up period (Supplementary Table S1 and Figure 3 ).

With restriction to cases with screening VOC results, VE against COVID-19 was higher for non-VOC than VOC among single-dose (77.0%, 95%CI: 72.6-80.7 versus 62.5%, 95%CI: 57.4-67.0) but not two-dose recipients (86.5%, 95%CI: 56.8-95.8 versus 93.5%, 95%CI: 88.7-96.3). The Alphaspecific VE did not differ from VE against any VOC (including those with undetermined lineage) (Table 2) but was consistently lower than for non-VOC across the entire follow-up period ( Figure   4 ). Among 90 hospitalized cases, 63 were analysed for VOC with the only vaccinated case bearing the Alpha variant.

Adjustment for the presence of comorbidity did not meaningfully affect VE estimates (data not shown). In analyses stratified by testing indication, one-dose VE was lower for COVID-19 compatible symptoms (62.7%, 95%CI: 58.6-66.4) versus outbreak-(73.0%, 95%CI: 64.7-79.4) or . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint screening-related testing (73.1%, 95%CI: 64.9-79.4). Two-dose estimates were higher for HCWs tested for symptomatic illness but with overlapping 95%CIs (Supplementary Table S1 ).

In this observational study, we report single-dose mRNA VE of 70% against any SARS-CoV-2 infection and 73% against COVID-19 illness among HCWs in Quebec, Canada. Although VE was higher at 86% and 93%, respectively, after a second dose, VE against COVID-19 hospitalization was comparably high at >95% for both one-and two-dose recipients. Importantly, we provide the longest single-dose vaccination follow-up to date, showing substantial protection maintained for at least 16 weeks after receipt of just one dose of mRNA vaccine. Overall, our findings reinforce the recommendation for second-dose deferral and show that the interval between doses can be extended to at least four months where indicated due to scarce vaccine supply.

Other observational studies from the US, Israel and Europe have reported comparable Pfizer-BioNTech VE among HCWs beginning 14 and 7 days after dose one or two, respectively, but these involved only short follow-up periods. In two US studies, single-dose VE among HCWs, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. infections was <30% in mid-March (week 12) but increased to >90% at the end of the study, may have contributed to an apparent but perhaps artefactual decline in overall single-dose protection across the analysis period. Furthermore, with respect to the question of potential waning of single-dose vaccine protection, we highlight an important methodological issue, critical for other investigators to consider. In . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint particular, we illustrate the impact that confounding by indication can have when averaging VE across sub-groups with different exposure risks and who are sequentially prioritized or targeted for vaccination on that basis. HCWs earliest prioritized for vaccination because of highest baseline infection risk will also contribute most to the longest post-vaccination analysis intervals.

In pooled analysis, their systematically higher infection risk and lower VE will lead to an overall, but erroneous, impression of declining single-dose VE generally with time since vaccination.

Conversely, with appropriate stratification based upon underlying differential in exposure and infection risk, we show single-dose VE to have been stable across the analysis period including both earlier and later prioritized HCW sub-sets. Properly addressing that methodological bias, we demonstrate no evidence for decrease in single-dose VE across a four-month follow-up period.

This study has limitations, foremost related to its observational design, subject to bias and confounding, and reliance on surveillance data subject to misclassification and missing information. Like others we could not fully adjust for differential exposure risk or fully ascertain the symptom profile notably after specimen testing. Despite easy access to testing, some asymptomatic infections were likely missed. HCWs with undetected infections before the study period could not be excluded leading to bias due to undiagnosed cases among vaccinated . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. 11. Comité sur l'immunization du Québec. Stratégie de vaccination contre la COVID-19 : report de la 2e dose en contexte de pénurie. Available at:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. Figure 1 . Vaccination coverage in the cohort of healthcare workers and total number of reported COVID-19 cases in the population per week, Quebec, Canada.

Abbreviations: VE=Vaccine effectiveness; CI=Confidence Interval . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint Figure 3 . Vaccine effectiveness against COVID-19 in healthcare workers vaccinated before January 31 st 2021 (highest contacts with patients) and those vaccinated after February 20 th 2021 (fewer contacts with patients) by interval since vaccination Abbreviations: VE=Vaccine effectiveness; CI=Confidence Interval . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint Figure 4 . Vaccine effectiveness against COVID-19 by variant of concern (VOC) status (non-VOC or Alpha variant) by interval since vaccination Abbreviations: VE=Vaccine effectiveness; VOC=Variants of concern; CI=Confidence Interval . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260445 doi: medRxiv preprint

National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 Vaccines. Ottawa: NACI. Available at

We would like to thank Louis Rochette for his work on preparing the healthcare workers' dataset.